Company news
Kalaris Therapeutics, Inc. news in 2023
Kalaris Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
December 21, 2023
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
November 15, 2023
AlloVir Reports Second Quarter 2023 Financial Results
August 2, 2023
AlloVir Announces Proposed Public Offering of Common Stock
June 20, 2023
AlloVir Announces Pricing of Public Offering of Common Stock
June 20, 2023
AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)
June 4, 2023
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
May 15, 2023
AlloVir Reports First Quarter 2023 Financial Results
May 3, 2023
AlloVir to Present at the BofA Securities 2023 Health Care Conference
April 30, 2023
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
April 25, 2023
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
February 14, 2023
AlloVir to Participate in the SVB Securities Global Biopharma Conference
January 31, 2023
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
January 8, 2023
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023